Biocon Biologics partners with National Cancer Society of Malaysia
To launch a Patient Assistance Program (PAP) in Malaysia
Biocon Biologics has partnered with the National Cancer Society of Malaysia (NCSM), a prominent not-for-profit cancer organization, to launch a Patient Assistance Program (PAP) in Malaysia aimed at improving access to affordable, high-quality biosimilars for underserved cancer patients in Malaysia.
Biocon Biologics will provide quality-assured biosimilars from its oncology portfolio, including Trastuzumab, Pegfilgrastim and Bevacizumab, to NCSM, which will manage patient enrolment and medicine supply as part of its healthcare services. This collaboration combines Biocon's expertise in biosimilars with NCSM's community outreach to enhance cancer care accessibility and affordability in Malaysia.
The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints.
The MoU was signed during the National Cancer Congress Malaysia 2025 event, emphasizing a commitment to improving patient-centric healthcare.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
21 hours ago
- Business Standard
Biocon Biologics partners with National Cancer Society of Malaysia
To launch a Patient Assistance Program (PAP) in Malaysia Biocon Biologics has partnered with the National Cancer Society of Malaysia (NCSM), a prominent not-for-profit cancer organization, to launch a Patient Assistance Program (PAP) in Malaysia aimed at improving access to affordable, high-quality biosimilars for underserved cancer patients in Malaysia. Biocon Biologics will provide quality-assured biosimilars from its oncology portfolio, including Trastuzumab, Pegfilgrastim and Bevacizumab, to NCSM, which will manage patient enrolment and medicine supply as part of its healthcare services. This collaboration combines Biocon's expertise in biosimilars with NCSM's community outreach to enhance cancer care accessibility and affordability in Malaysia. The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints. The MoU was signed during the National Cancer Congress Malaysia 2025 event, emphasizing a commitment to improving patient-centric healthcare.
&w=3840&q=100)
Business Standard
2 days ago
- Business Standard
Decision on merger with Biocon Biologics soon, says Siddharth Mittal
We are talking about the GLP-1 opportunity and our strong franchise in insulins. There is a huge demand in the global diabetes-obesity segment, said Siddharth Mittal Sohini Das Mumbai Listen to This Article Biocon successfully raised ₹4,500 crore through a qualified institutional placement (QIP) last week that saw strong interest from both Indian and global investors. It is also considering a merger of Biocon Biologics with Biocon to tap into business and scientific synergies rather than listing Biocon Biologics. In a virtual interaction with Sohini Das, Siddharth Mittal, chief executive officer (CEO) and managing director (MD) of Biocon outlined his plans. Edited excerpts: Your QIP was successful. What do you plan to do with the proceeds? There was very strong investor demand. The Board had approved raising up to ₹4,500 crore in one,
&w=3840&q=100)
Business Standard
22-05-2025
- Business Standard
Biocon Biologics gets six-month extension of insulin supply in Malaysia
Biocon arm Biocon Biologics Limited (BBL) said in a statement that the Malaysian Ministry of Health has extended the insulin supply contract with the company. 'Biocon Biologics is pleased to inform that the Government of Malaysia has agreed to extend the current contract period of 36 months under the existing insulin supply agreement with its subsidiary in Malaysia, Biocon Sdn. Bhd., and Duopharma Marketing Sdn. Bhd. (DMktg), for an additional six (6) months, effective from 29 April 2025 until 28 October 2025,' said a company spokesperson. Biocon Biologics further stated that it has been the Ministry of Health's partner of choice for insulin supply in Malaysia for nearly a decade. Its recombinant human insulin products are manufactured at a state-of-the-art facility in Johor and distributed via commercial partner DMktg. The current supply contract runs through April 2025. The amendment to the contract will be formalised through a supplementary agreement between the Ministry of Health (MoH), Duopharma Marketing (DMktg), and Biocon. Biocon Biologics said it remains committed to providing affordable access to life-saving insulins for people with diabetes in Malaysia and globally. The company has been supplying insulin products to Malaysia for over a decade. Additionally, it operates an integrated insulin manufacturing facility in Johor, in southern Malaysia. Biocon Biologics received US Food and Drug Administration (FDA) approval for this facility earlier this year, in January. Let me know if you'd like a version tailored for social media, a press note, or infographic format.
